Key result
Baseline antiplatelets suppress platelet P-selectin expression, though ~25% show high on-clopidogrel reactivity.
Why the study?
Does baseline aspirin or clopidogrel therapy suppress remotely measured ex vivo stimulated platelet surface P-selectin expression in patients presenting with acute ischaemic stroke or transient ischaemic attack?
Cross-Sectional (n=688)
Yes
Does baseline aspirin or clopidogrel therapy suppress remotely measured ex vivo stimulated platelet surface P-selectin expression in patients presenting with acute ischaemic stroke or transient ischaemic attack?
Remote flow cytometric assessment of platelet P-selectin expression is feasible across multicentre stroke clinics and reveals that nearly one-quarter of acute stroke/TIA patients taking clopidogrel have high on-treatment platelet reactivity.
Answers are grounded in this paper and cite their sources.
Remote P-selectin testing confirms antiplatelet effects in acute stroke/TIA; high clopidogrel nonresponse rate leaves open utility of reactivity-guided therapy.
Background . The TARDIS trial assessed the safety and efficacy of intensive versus guideline antiplatelet agents given for one month in patients with acute stroke or TIA. The aim of this substudy was to assess the effect of antiplatelet agents taken at baseline on platelet function reactivity and activation. Methods . Platelet function, assessed by remotely measured surface expression of P-selectin, was assessed in patients at their time of randomisation. Data are median fluorescence values. Results . The aspirin P-selectin test demonstrated that platelet expression was lower in 494 patients taking aspirin than in 162 patients not: mean 210 (SD 188) versus 570 (435), difference 360.3 (95% CI 312.2–408.4) (2p<0.001). Aspirin did not suppress P-selectin levels below 500 units in 23 (4.7%) patients. The clopidogrel test showed that platelet reactivity was lower in 97 patients taking clopidogrel than in 585 patients not: 655 (296) versus 969 (315), difference 314.5 (95% CI 247.3–381.7) (2p<0.001). Clopidogrel did not suppress P-selectin level below 860 units in 24 (24.7%) patients. Conclusions . Aspirin and clopidogrel suppress stimulated platelet P-selectin, although one-quarter of patients on clopidogrel have high on-treatment platelet reactivity. Platelet function testing may be performed remotely in the context of a large multicentre trial. Trial registration ISRCTN47823388 .
No takes yet. Share an insight, caveat, or question.
Bath et al. (2017) conducted a cross-sectional in Acute ischaemic stroke or transient ischaemic attack (TIA) (n=688). Baseline antiplatelet therapy (aspirin or clopidogrel) vs. No aspirin or no clopidogrel at baseline was evaluated on Arachidonic acid-stimulated platelet surface P-selectin expression (median fluorescence) (MD 360.3, 95% CI 312.2-408.4, p=<0.001). Baseline aspirin and clopidogrel suppressed stimulated platelet P-selectin expression, though 24.7% on clopidogrel had high reactivity.
Synapse has enriched 10 related papers. Consider them for comparative context: